The Current Ratio as of November 2024 (TTM) for MoonLake Immunotherapeutics (MLTX) is 43.71

According to MoonLake Immunotherapeutics’s latest financial reports and current stock price. The company's current Current Ratio is 43.71. This represents a change of -15.10% compared to the average of 51.49 of the last 4 quarters.

MoonLake Immunotherapeutics (MLTX) Historical Current Ratio (quarterly & annually)

How has MLTX Current Ratio performed in the past?

The mean historical Current Ratio of MoonLake Immunotherapeutics over the last ten years is 18.74. The current 43.71 Current Ratio has changed 23.22% with respect to the historical average. Over the past ten years (40 quarters), MLTX's Current Ratio was at its highest in in the June 2023 quarter at 70.97. The Current Ratio was at its lowest in in the December 2020 quarter at 0.

MoonLake Immunotherapeutics (MLTX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of MoonLake Immunotherapeutics Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

MoonLake Immunotherapeutics (MLTX) Average Current Ratio

How has MLTX Current Ratio performed in the past?

The current Current Ratio of MoonLake Immunotherapeutics (MLTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

MoonLake Immunotherapeutics (MLTX) Current Ratio vs. Peers

How is MLTX’s Current Ratio compared to its peers?

MoonLake Immunotherapeutics’s Current Ratio is less than Terns Pharmaceuticals, Inc. (0), greater than Day One Biopharmaceuticals, Inc. (21.02), greater than Acumen Pharmaceuticals, Inc. (14.62), greater than Amylyx Pharmaceuticals, Inc. (17.37), greater than Aerovate Therapeutics, Inc. (4.66), greater than Enliven Therapeutics, Inc. (6.51), greater than Structure Therapeutics Inc. (14.39), greater than Compass Therapeutics, Inc. (41.38), greater than Ventyx Biosciences, Inc. (40.74), greater than Nuvalent, Inc. (14.19), greater than Cerevel Therapeutics Holdings, Inc. (17.44), greater than Travere Therapeutics, Inc. (10.22), greater than Arcellx, Inc. (1.71), greater than Akero Therapeutics, Inc. (6.01), greater than 89bio, Inc. (24.89), greater than Pliant Therapeutics, Inc. (13.92), greater than null (14.47),

Build a custom stock screener for MoonLake Immunotherapeutics (MLTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like MoonLake Immunotherapeutics using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

MoonLake Immunotherapeutics (MLTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like MoonLake Immunotherapeutics or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.